Is GlobalFoundries On The Verge Of A Breakout?
GLOBALFOUNDRIES Inc. (NASDAQ:GFS) is as a semiconductor foundry whose chips…
Sell
50
CAPR Quote, Financials, Valuation and Earnings
Last price:
$11.34
Seasonality move
:
6.32%
Day range:
$10.17 - $11.41
52-week range:
$3.52 - $23.40
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.18x
P/B ratio:
3.94x
Volume:
3.4M
Avg. volume:
2.5M
1-year change:
74.76%
Market cap:
$503.2M
Revenue:
$22.3M
EPS (TTM):
-$1.42
Analysts' Opinion
-
Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.13, Capricor Therapeutics has an estimated upside of 282.61% from its current price of $11.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $25.00 representing -127.07% downside risk from its current price of $11.01.
Fair Value
-
According to the consensus of 4 analysts, Capricor Therapeutics has 282.61% upside to fair value with a price target of $42.13 per share.
CAPR vs. S&P 500
-
Over the past 5 trading days, Capricor Therapeutics has overperformed the S&P 500 by 50.22% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Capricor Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Capricor Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Capricor Therapeutics reported revenues of $11.1M.
Earnings Growth
-
Capricor Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Capricor Therapeutics reported earnings per share of -$0.53.
Enterprise value:
358.5M
EV / Invested capital:
--
Price / LTM sales:
19.18x
EV / EBIT:
--
EV / Revenue:
16.10x
PEG ratio (5yr expected):
-0.21x
EV / Free cash flow:
-7.60x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-49.36%
Net Income Margin (TTM):
-181.71%
Return On Equity:
-75.99%
Return On Invested Capital:
-75.99%
Operating Margin:
-69.16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | $27.1M | -- | $4.9M | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$30.1M | -$26.2M | -$57.3M | -$10.3M | -$25M | |
| EBITDA | -$29.4M | -$25M | -$55.8M | -$9.9M | -$24.6M | |
| Diluted EPS | -$1.17 | -$0.83 | -$1.42 | -$0.31 | -$0.53 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $42.6M | $59.6M | $46.6M | $41.4M | $146.3M | |
| Total Assets | $43.5M | $64.9M | $53.9M | $49.4M | $153.8M | |
| Current Liabilities | $3.8M | $14.3M | $37.1M | $26.4M | $22.3M | |
| Total Liabilities | $7.2M | $40.3M | $47.7M | $31M | $26.1M | |
| Total Equity | $36.4M | $24.6M | $6.2M | $18.4M | $127.6M | |
| Total Debt | $318.2K | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$14.9M | -$31.1M | -$45.2M | -$1.3M | -$6.4M | |
| Cash From Investing | -$37.7M | -$1.2M | -$82.8M | -$9.5M | $23.9M | |
| Cash From Financing | $4.9M | $27.9M | $150.5M | $2.3M | $50.4K | |
| Free Cash Flow | -$18.1M | -$33.3M | -$47.2M | -$1.9M | -$7.6M | |
CAPR
Sector
Market Cap
$503.2M
$34.2M
Price % of 52-Week High
47.05%
43.73%
Dividend Yield
0%
0%
Shareholder Yield
-24.22%
-0.66%
1-Year Price Total Return
74.76%
-41.71%
Beta (5-Year)
0.853
0.657
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.60
200-day SMA
Sell
Level
$12.42
Bollinger Bands (100)
Sell
Level
10.14 - 14.94
Chaikin Money Flow
Sell
Level
-104.8M
20-day SMA
Buy
Level
$10.12
Relative Strength Index (RSI14)
Buy
Level
55.87
ADX Line
Buy
Level
22.21
Williams %R
Neutral
Level
-31.7986
50-day SMA
Buy
Level
$10.79
MACD (12, 26)
Sell
Level
-0.51
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
492.2M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (13.7532)
Sell
CA Score
(Annual)
Level (-0.993)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.5273)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Stock Forecast FAQ
In the current month, CAPR has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CAPR average analyst price target in the past 3 months is $42.13.
-
Where Will Capricor Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Capricor Therapeutics share price will rise to $42.13 per share over the next 12 months.
-
What Do Analysts Say About Capricor Therapeutics?
Analysts are divided on their view about Capricor Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Capricor Therapeutics is a Sell and believe this share price will drop from its current level to $25.00.
-
What Is Capricor Therapeutics's Price Target?
The price target for Capricor Therapeutics over the next 1-year time period is forecast to be $42.13 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CAPR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Capricor Therapeutics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CAPR?
You can purchase shares of Capricor Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Capricor Therapeutics shares.
-
What Is The Capricor Therapeutics Share Price Today?
Capricor Therapeutics was last trading at $11.34 per share. This represents the most recent stock quote for Capricor Therapeutics. Yesterday, Capricor Therapeutics closed at $11.01 per share.
-
How To Buy Capricor Therapeutics Stock Online?
In order to purchase Capricor Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Dick’s Sporting Goods Buying Foot Locker Smart?
Last week, Dick’s Sporting Goods (NYSE:DKS) announced that it would…
Is Ginkgo Bioworks Stock a Good Buy?
Biotech innovator Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) has had better…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
71
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
55
RGC alert for May 21
Regencell Bioscience Holdings [RGC] is down 3.24% over the past day.
Buy
64
AKRO alert for May 21
Akero Therapeutics [AKRO] is up 1.56% over the past day.
Buy
76
AGYS alert for May 21
Agilysys [AGYS] is down 1.32% over the past day.
